JAK inhibitor labeling in Canada updated to include risks of MACE, fatal VTE and cancer for tofacitinib (Xeljanz) (also applied to Cibinqo, Inrebic, Jakavi, Olumiant, Rinvoq Xeljanz) https://t.co/FEbHE4wN3I https://t.co/EN80i9cY5h